Epitopix Purchased by Vaxxinova and Remains on Campus as Global Company’s U.S. Headquarters
Willmar, MN, March 6, 2018 – The MinnWest Technology Campus is proud to share some exciting
news about Epitopix, one of our founding tenants. Epitopix was sold to Vaxxinova, a global animal health company that operates in more than 50 countries. Vaxxinova, owned by Dutch holding company EW-Group, will leverage this acquisition to enter the U.S. market and use the MinnWest Technology Campus as their U.S. headquarters. They also have locations in Brazil, Germany, Italy, Norway, Japan and Jordan.
Epitopix, LLC was formed in 2002 to commercialize Siderophore Receptor and Porin (SRP®) technology, a revolutionary vaccine that immunizes against bacterial infections utilizing a cell-free purified extract of SRP proteins, and to discover new vaccine technologies that improve animal health and food safety.
“The acquisition by Vaxxinova provides Epitopix a chance to accelerate our growth in the poultry and livestock vaccine markets,” according to Dr. Jim Sandstrom, Managing Director of Epitopix. “Since the founding of Epitopix, we have been under the protective wing of our parent, Willmar Poultry Company. Now we’ll have the ability to fly, with the experience of an international team to guide us and new resources under our wings.”
It has been a pleasure having Epitopix as a tenant and we welcome Vaxxinova to the MinnWest Technology Campus as their U.S. headquarters.
The purpose of the MinnWest Technology Campus is to create a place where innovation meets collaboration to help businesses break new ground, set new standards and reach new heights of personal and professional success. Vaxxinova’s ability to continue building on the advancements made by Epitopix on a global level align with the mission of our campus.